CROSSJECT Aktie

2,19 EUR +0,05 EUR +2,10 %

11:47:56

STU

CROSSJECT jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.114,16 Mio. EUR

Div. Rendite0,00%

WKNA1XEH4

ISINFR0011716265

SymbolCRJTF

CROSSJECT Aktien News

Sortieren:Datum Meistgelesen

11.06.25GlobeNewswireCROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children

04.06.25GlobeNewswireLaunch of a capital increase with preferential subscription rights for nearly 5 million euros

03.06.25GlobeNewswireMaxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of €4.00

WerbungCROSSJECT-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

27.05.25GlobeNewswireCROSSJECT implements new manufacturing module to scale-up the ZENEO® Factory ‘s versatility and capacity in anticipation of full product pipeline deployment

20.05.25GlobeNewswireCROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approva

15.05.25GlobeNewswireCROSSJECT’s ZENEO® needle-free autoinjector consistently matches depth of traditional intramuscular injections and exceeds the standards needle length of currently utilized auto-injectors

07.05.25GlobeNewswireCROSSJECT provides updates on the EUA filing of ZEPIZURE®

30.04.25GlobeNewswireMise à disposition du rapport financier annuel 2024

27.03.25GlobeNewswireCROSSJECT reports financial results for 2024

25.03.25GlobeNewswireCROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program

18.03.25GlobeNewswireCROSSJECT achieves key ZEPIZURE® manufacturing batch stability milestones

12.02.25GlobeNewswireCrossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board

06.02.25GlobeNewswireCOMPLETION OF THE TRANSACTIONS ANNOUNCED IN DECEMBER 2024 RELATING TO THE AMENDMENT OF THE CONVERTIBLE BONDS SUBSCRIBED BY AN ENTITY AFFILIATED TO HEIGHTS CAPITAL MANAGEMENT, INC. (“HEIGHTS”) AND THE

19.12.24GlobeNewswireCrossject confirms ZEPIZURE® supply chain readiness with another successful ISO audit for Quality Management System

11.12.24GlobeNewswireCrossject announces the pricing of its reserved capital increase and warrants issuance for an aggregate amount of EUR 7.2M

10.12.24GlobeNewswireCrossject launches reserved capital increase and warrants issuance for an aggregate amount of at least €7m

09.12.24GlobeNewswireCrossject and the U.S. Department of Defense Relaunch Joint Research on Needle-free Autoinjectors, Extending Their Cooperative Research and Development Agreement

13.11.24GlobeNewswireCrossject’s ZENEO® Auto-Injector's usability further demonstrated in extreme HAZMAT conditions

22.10.24GlobeNewswireCrossject reports strong manufacturing progress with its epilepsy rescue therapy ZEPIZURE® ahead of filing U.S. Emergency Use Authorization

26.09.24GlobeNewswireCrossject announces its eligibility for France’s PEA-PME investment scheme

23.09.24GlobeNewswireCrossject reports financial results and business highlights for the first six months of 2024

17.09.24GlobeNewswireCrossject to report first-half 2024 financial results and host webcast on September 23, 2024

22.08.24GlobeNewswireCrossject to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

19.08.24GlobeNewswireCrossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment

18.07.24GlobeNewswireCrossject achieves key ZEPIZURE® manufacturing milestone

15.07.24GlobeNewswireCrossject to attend H.C. Wainwright 26th Annual Global Investment Conference

10.07.24GlobeNewswireCrossject is awarded a 6.9 million euros financing from the French Government, as part of the France 2030 innovation plan, to accelerate the development of ZENEO® Epinephrine

26.06.24GlobeNewswireCrossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study and its own, recently published, bioequivalence study

12.06.24GlobeNewswireCrossject appoints Dan Chiche, MD as Chief Medical Officer North America

04.06.24GlobeNewswireCrossject announces highly successful closing of its €8 million rights offering

30.05.24GlobeNewswireCrossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy

02.05.24GlobeNewswireCrossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe

25.04.24GlobeNewswireCrossject reports audited financial results for 2023

02.04.24GlobeNewswireCrossject trading on Euronext to resume as usual on Wednesday April 3

02.04.24GlobeNewswireCrossject advances in its U.S. Strategy and reports Financial Results for 2023

08.03.24GlobeNewswireCrossject gender equality score reaches 96/100 in 2024

27.02.24GlobeNewswireCrossject obtains a financing up to €12 million, in two tranches

06.02.24GlobeNewswireCrossject provides strategic update on priorities for 2024

01.02.24GlobeNewswireCrossject to host a business briefing on commercial strategy on February 6 at 17:30 CET

09.01.24GlobeNewswireCrossject to present at Biotech Showcase on January 9 at 16:30 PT

CROSSJECT News

CROSSJECT News: auf dieser Seite finden Sie alle CROSSJECT News und Nachrichten zur CROSSJECT Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch CROSSJECT News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um CROSSJECT News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.